Marugame, Japan
Marugame, Japan

Time filter

Source Type

Patent
Fushimi Pharmaceutical Company, Teikoku Seiyaku Co. and Kagawa University | Date: 2011-09-14

A method of utilizing the physiological activity of a rare saccharide, wherein physiological-activity sensitive cells are treated with the rare saccharide to modify the function of the cells. A composition containing, as an active ingredient, a rare saccharide which is introduced into physiological-activity sensitive cells and has an effect of modifying the function of the cells. The cells are human cells. The composition is a functional food, a drug, or a cosmetic. The rare saccharide is D-allose, and the cells are selected from the group consisting of cancer-cell proliferation inhibitory activity sensitive cells and active-oxygen production inhibitory activity sensitive cells.


Asano R.,Fushimi Pharmaceutical Co. | Nagami A.,Prefectural University of Hiroshima | Fukumoto Y.,Prefectural University of Hiroshima | Yazama F.,Prefectural University of Hiroshima | And 3 more authors.
Bioorganic and Medicinal Chemistry | Year: 2013

Three new water-soluble chlorin derivatives 3, 5 and 8 for potential use as photosensitizers in photodynamic therapy (PDT) for cancer were synthesized from photoprotoporphyrin IX dimethyl ester (1). The in vivo biodistribution and clearance of chlorin derivatives 3, 5 and 8 were investigated in tumor-bearing mice. Iminodiacetic acid derivative 8 showed the greatest tumor-selective accumulation among the new chlorin derivatives with maximum accumulation in tumor tissue at 3 h after intravenous injection and rapid clearance from normal tissues within 24 h after injection. The in vivo therapeutic efficacy of PDT using 8 was evaluated by measuring tumor growth rates in tumor-bearing mice with 660 nm light-emitting diode irradiation at 3 h after injection of 8. Tumor growth was significantly inhibited by PDT using 8. These results indicate that iminodiacetic acid derivative 8 is useful as a new photosensitizer to overcome the disadvantages of photosensitizers that are currently in clinical use. © 2013 Elsevier Ltd. All rights reserved.


There are provided a liquid preparation for oral administration which contains barium that is likely to be mixed with residues and is less likely to be precipitated in the intestinal tract, and a liquid preparation for oral administration and a composition for imaging a digestive tract which contain barium and enable the reduction of the dose of an intestinal tract cleaning solution in a the intestinal tract pretreatment. That is, there are provided an orally administered liquid preparation which contains barium and one or more types of thickening agents selected from the group consisting of a natural polysaccharide and a cellulose-based polymer, in which the viscosity at a shear rate of 21.54 s^(1 )is 100 mPas or greater and the viscosity at a shear rate of 464.1 s^(1 )is 5 mPas to 90 mPas, and the particle diameter D10 which is the particle diameter when the accumulation value in a volume cumulative distribution of the barium becomes 10% is 0.30 m to 0.80 m and the particle diameter D90 is 1.0 m to 10 m; and a liquid preparation for oral administration used in CT colonography digestive tract imaging, which contains barium and a water-soluble polymer or a saline purgative agent, and is taken in an amount of 50 mL to 2000 mL all at once or in several parts over a period of time on the day before the CT colonography is performed.


Kato A.,University of Toyama | Kunimatsu T.,University of Toyama | Yamashita Y.,University of Toyama | Adachi I.,University of Toyama | And 2 more authors.
Journal of Agricultural and Food Chemistry | Year: 2013

1,5-Anhydro-d-glucitol (1,5-AG) is fairly widespread in food products. It is also one of the major polyols in the human body, and its concentration is homeostatically regulated. We report here on the beneficial effects of 1,5-AG in preventing hyperglycemia and its role in improving metabolic syndrome. The findings revealed that it does not affect blood glucose levels itself under normal conditions but clearly has a suppressive effect on the levels of dietary sugars, such as glucose, maltose, and sucrose. A long-term administration study revealed that feeding db/db diabetic mice 3% 1,5-AG for 8 weeks significantly decreased blood glucose levels compared to untreated mice (339 ± 30 versus 438 ± 34 mg/dL; p < 0.05). Furthermore, this treatment also significantly suppressed serum cholesterol levels (110.2 ± 18.0 versus 168.4 ± 9.8 mg/dL; p < 0.01). 1,5-AG did not inhibit intestinal α-glucosidase activities but regulated liver glucose levels via affecting both the glycogenolysis and gluconeogenesis pathways. Furthermore, the oral administration of 1,5-AG significantly increased urinary glucose excretion in hyperglycemic conditions. These results clearly suggest that dietary 1,5-AG acts as a modulator of glucose levels in hyperglycemia. 1,5-AG therefore represents a new class of promising functional sweeteners, where the daily consumption of 1,5-AG with meals could inhibit the progress of hyperglycemia and metabolic syndrome. © 2012 American Chemical Society.


Patent
University of Toyama and Fushimi Pharmaceutical Co. | Date: 2016-03-02

A collagen production promoter in cells, containing at least one member selected from the group consisting of 1,5-anhydro-D-glucitol and derivatives thereof; and a composition containing the collagen production promoter. Since the collagen production promoter containing 1,5-AG or derivatives thereof of the present invention is suitably used as cosmetics, medicinal formulations, foods, and the like, for promoting collagen production in cells, for example, preventing and/or improving wrinkles of skin.


Weikel A.L.,Pennsylvania State University | Owens S.G.,Pennsylvania State University | Fushimi T.,Fushimi Pharmaceutical Co. | Allcock H.R.,Pennsylvania State University
Macromolecules | Year: 2010

The preparation of phosphazenes that possess reversible cross-linking groups to control mechanical stability and hydrolysis has been accomplished using cysteine and methionine amino acid side groups. Small molecule models and linear polymeric phosphazenes that contain methionine ethyl ester and cysteine ethyl disulfide ethyl ester side groups were synthesized. Protection of the free thiol groups was carried out to circumvent unwanted cross-linking of the phosphazenes through the cysteine ethyl ester N- and S-termini. Cyclic trimeric cysteine ethyl disulfide ethyl ester model compounds were deprotected by S - S bond cleavage using β-mercaptoethanol, dithiothreitol (DTT), and zinc in aqueous hydrochloric acid. For the high polymeric derivatives, the extent of S - S bond cleavage varied depending on the deprotection method used. With the exception of the Zn/HCl method, the resultant deprotected polymers were soluble in common organic solvents and underwent minimal chain cleavage during the reaction sequence. The protected or deprotected high polymers are candidates for reversible cross-linking in drug delivery systems and for cross-link stabilization of tissue engineering scaffolds. © 2010 American Chemical Society.


Lee D.K.Y.,Pennsylvania State University | Jackson A.-M.S.,Pennsylvania State University | Fushimi T.,Fushimi Pharmaceutical Co. | Yennawar H.,Pennsylvania State University | Allcock H.R.,Pennsylvania State University
Dalton Transactions | Year: 2010

Two novel cyclic phosphazenes with asymmetric spiro rings were synthesized via reactions of hexachlorocyclotriphosphazene with chiral amino alcohol residues. The reactions showed preferential formation of the cis isomer possibly due to the delocalization of the lone pair electrons of the spirocylic nitrogen, which reduces its ability to solvate protons. Crystals of these phosphazenes were analyzed by X-ray crystallography which confirmed the formation of cis isomers and showed their ability to include guest molecules within the crystal lattices. The selective inclusion of epoxides by one of the phosphazenes was an effective method for the separation of thermally sensitive guest molecules. © 2010 The Royal Society of Chemistry.


Fushimi T.,Fushimi Pharmaceutical Co. | Allcock H.R.,Pennsylvania State University
Dalton Transactions | Year: 2010

Novel cyclotriphosphazenes with sulfur-containing spirocyclic side groups were synthesized and polymerized to cyclomatrix materials for potential optical applications. The cyclotriphosphazenes were designed to give a high content of the phosphazene unit and sulfur atoms, as well as the capability for polymerization by ring- opening of the side groups. The chemical structures of the monomers were confirmed by NMR spectrometry, mass spectrometry, and single-crystal X-ray diffraction. Transparent solids were obtained by thermal bulk polymerization, and these were analyzed by the use of DSC, infrared spectroscopy, and mass spectrometry. One of the resultant cyclomatrix polyphosphazenes had a refractive index at 589 nm of 1.6465 and an Abbe number of 39. The contribution of the phosphazene unit to the refractive index is discussed. © 2010 The Royal Society of Chemistry.


Patent
National University Corporation University Of Toyoma and Fushimi Pharmaceutical Co. | Date: 2014-03-26

A collagen production promoter in cells, containing at least one member selected from the group consisting of 1,5-anhydro-D-glucitol and derivatives thereof; and a composition containing the collagen production promoter. Since the collagen production promoter containing 1,5-AG or derivatives thereof of the present invention is suitably used as cosmetics, medicinal formulations, foods, and the like, for promoting collagen production in cells, for example, preventing and/or improving wrinkles of skin.


Trademark
FUSHIMI Pharmaceutical Co. | Date: 2011-01-11

Industrial chemicals; fire retardant chemicals. Industrial oils; industrial greases.

Loading Fushimi Pharmaceutical Co. collaborators
Loading Fushimi Pharmaceutical Co. collaborators